Dermata Therapeutics Inc. (DRMA)
| Bid | 0.75 |
| Market Cap | 5.24M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.29M |
| EPS (ttm) | -8.03 |
| PE Ratio (ttm) | -0.11 |
| Forward PE | -0.82 |
| Analyst | Buy |
| Ask | 0.86 |
| Volume | 51,340 |
| Avg. Volume (20D) | 1,500,159 |
| Open | 0.83 |
| Previous Close | 0.82 |
| Day's Range | 0.80 - 0.87 |
| 52-Week Range | 0.69 - 6.17 |
| Beta | 0.58 |
About DRMA
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phas...
Analyst Forecast
According to 1 analyst ratings, the average rating for DRMA stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 590.45% from the latest price.
Stock Forecasts
2 weeks ago · accessnewswire.com
Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial - - Additional data analysis revealed that XYNGA...
1 month ago · accessnewswire.com
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 - - The Company recently entered into a Clinic...
